German Center for Neurodegenerative Diseases (DZNE), Rostock/Greifswald, Rostock, Germany.
Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Karolinska Institutet, Stockholm, Sweden.
Alzheimers Res Ther. 2021 Feb 19;13(1):49. doi: 10.1186/s13195-021-00785-9.
Previous research has described distinct subtypes of Alzheimer's disease (AD) based on the differences in regional patterns of brain atrophy on MRI. We conducted a data-driven exploration of distinct AD neurodegeneration subtypes using FDG-PET as a sensitive molecular imaging marker of neurodegenerative processes.
Hierarchical clustering of voxel-wise FDG-PET data from 177 amyloid-positive patients with AD dementia enrolled in the Alzheimer's Disease Neuroimaging Initiative (ADNI) was used to identify distinct hypometabolic subtypes of AD, which were then further characterized with respect to clinical and biomarker characteristics. We then classified FDG-PET scans of 217 amyloid-positive patients with mild cognitive impairment ("prodromal AD") according to the identified subtypes and studied their domain-specific cognitive trajectories and progression to dementia over a follow-up interval of up to 72 months.
Three main hypometabolic subtypes were identified: (i) "typical" (48.6%), showing a classic posterior temporo-parietal hypometabolic pattern; (ii) "limbic-predominant" (44.6%), characterized by old age and a memory-predominant cognitive profile; and (iii) a relatively rare "cortical-predominant" subtype (6.8%) characterized by younger age and more severe executive dysfunction. Subtypes classified in the prodromal AD sample demonstrated similar subtype characteristics as in the AD dementia sample and further showed differential courses of cognitive decline.
These findings complement recent research efforts on MRI-based identification of distinct AD atrophy subtypes and may provide a potentially more sensitive molecular imaging tool for early detection and characterization of AD-related neurodegeneration variants at prodromal disease stages.
先前的研究基于 MRI 上脑萎缩的区域模式差异,描述了阿尔茨海默病(AD)的不同亚型。我们使用 FDG-PET 作为神经退行性过程的敏感分子成像标志物,对 AD 神经退行性变的不同亚型进行了数据驱动的探索。
对 177 名 AD 痴呆症患者的 FDG-PET 数据进行基于体素的层次聚类,这些患者均为淀粉样蛋白阳性,他们均来自阿尔茨海默病神经影像学倡议(ADNI)。该方法用于识别 AD 的不同代谢低下亚型,然后进一步根据临床和生物标志物特征对其进行特征描述。随后,我们根据所确定的亚型对 217 名淀粉样蛋白阳性的轻度认知障碍(“前驱 AD”)患者的 FDG-PET 扫描进行分类,并研究了他们在长达 72 个月的随访间隔内特定领域的认知轨迹以及向痴呆的进展情况。
确定了三种主要的代谢低下亚型:(i)“典型”(48.6%),表现为经典的后颞顶叶代谢低下模式;(ii)“边缘优势”(44.6%),以老年和以记忆为主的认知特征为特征;以及(iii)一种相对罕见的“皮质优势”亚型(6.8%),以年龄较轻和更严重的执行功能障碍为特征。在前驱 AD 样本中分类的亚型表现出与 AD 痴呆样本相似的亚型特征,并且进一步表现出不同的认知下降过程。
这些发现补充了基于 MRI 的 AD 不同萎缩亚型识别的最新研究努力,并且可能为早期检测和表征前驱疾病阶段的 AD 相关神经退行性变变体提供一种更敏感的分子成像工具。